Literature DB >> 8742682

Salivary substance P, 5-hydroxytryptamine, and gamma-aminobutyric acid levels in migraine and tension-type headache.

H Marukawa1, T Shimomura, K Takahashi.   

Abstract

Substance P, 5-hydroxytryptamine, and gamma-aminobutyric acid levels in saliva were measured in 55 patients with migraine during headache attacks (15 men and 40 women, average age 37.6 years), 36 patients with migraine in interictal periods (8 men and 28 women, average age 43.9 years), 48 patients with tension-type headache during headache attacks (18 men and 30 women, average age 47.3 years), and 25 patients with tension-type headache in interictal periods (10 men and 15 women, average age 48.6 years). Forty-three normal healthy volunteers composed the control group (17 men and 26 women, average age 32.7 years). Substance P levels in saliva were determined using competitive enzyme-linked immunosorbent assay, and were 26.9 +/- 45.1 pmol/mL in the patients with migraine during headache attacks, 30.0 +/- 59.7 pmol/mL in the patients with migraine in interictal periods, 243.5 +/- 1137 pmol/mL in the patients with tension-type headache during headache attacks, 101.3 +/- 364 pmol/mL in the patients with tension-type headache in interictal periods, and 21.2 +/- 17.4 pmol/mL in the healthy controls. 5-hydroxytryptamine levels in saliva were determined using reversed-phase high-performance liquid chromatography with electrochemical detection, and were 895 +/- 1075 ng/mL in the patients with migraine during headache attacks, 758 +/- 1375 ng/mL in the patients with migraine in interictal periods, 1646 +/- 1945 ng/mL in the patients with tension-type headache during active headache periods, 1167 +/- 1495 ng/mL in the patients with tension-type in headache-free periods, and 450 +/- 405 ng/mL in the healthy controls. Gamma-aminobutyric acid levels in saliva were determined using high-performance liquid chromatography with precolumn ortho-phthalaldehyde fluorescence detection. Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls. The salivary substance P and 5-hydroxytryptamine levels in the patients with tension-type headache during active headache periods were significantly higher than those in healthy controls. In contrast, we found no significant differences between the salivary gamma-aminobutyric acid levels in the patients with tension-type headache and healthy controls. The high levels of salivary substance P and 5-hydroxytryptamine in tension-type headache patients during headache periods might reflect release of substance P from the pain sensory system. Saliva could represent a fluid particularly suitable to the study of neuropeptide release under specific conditions such as migraine and tension-type headache.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8742682     DOI: 10.1046/j.1526-4610.1996.3602101.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  9 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Lifestyle, stress and cortisol response: Review I : Mental stress.

Authors:  S Fukuda; K Morimoto
Journal:  Environ Health Prev Med       Date:  2001-04       Impact factor: 3.674

3.  Serum MicroRNA Signatures in Migraineurs During Attacks and in Pain-Free Periods.

Authors:  Hjalte H Andersen; Meg Duroux; Parisa Gazerani
Journal:  Mol Neurobiol       Date:  2015-02-01       Impact factor: 5.590

4.  Effects of endodontic treatment on salivary levels of CGRP and substance P: a pilot study.

Authors:  Hakan Arslan; Ezgi Doğanay Yıldız; Serhat Köseoğlu
Journal:  Restor Dent Endod       Date:  2020-07-14

5.  The Association of Salivary Serotonin With Mood and Cardio-Autonomic Function: A Preliminary Report.

Authors:  Michał Seweryn Karbownik; Steven Daniel Hicks
Journal:  Front Psychiatry       Date:  2022-05-31       Impact factor: 5.435

Review 6.  Rizatriptan: an update of its use in the management of migraine.

Authors:  Keri Wellington; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Genetic and biochemical changes of the serotonergic system in migraine pathobiology.

Authors:  Claudia Francesca Gasparini; Robert Anthony Smith; Lyn Robyn Griffiths
Journal:  J Headache Pain       Date:  2017-02-13       Impact factor: 7.277

8.  Salivary serotonin does not correlate with central serotonin turnover in adult phenylketonuria (PKU) patients.

Authors:  Joseph Leung; Caroline Selvage; Taryn Bosdet; Jennifer Branov; Annie Rosen-Heath; Carole Bishop; Sandra Sirrs; Gabriella Horvath
Journal:  Mol Genet Metab Rep       Date:  2018-04-05

9.  Decrease in Salivary Serotonin in Response to Probiotic Supplementation With Saccharomyces boulardii in Healthy Volunteers Under Psychological Stress: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Michał Seweryn Karbownik; Joanna Kręczyńska; Anna Wiktorowska-Owczarek; Paulina Kwarta; Magdalena Cybula; Nebojša Stilinović; Tadeusz Pietras; Edward Kowalczyk
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-06       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.